Compare Equinix Inc (EQIX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Equinix Inc trades at $1,002.92 (market cap $100.85B), while Vertex Pharmaceuticals Incorporated trades at $479.31 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Equinix Inc pays a 1.93% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| EQIX | VRTX | |
|---|---|---|
Market Cap | $100.85B | $121.09B |
Sector | Real Estate | Health |
52-Week High | $1.12K | $529.59 |
52-Week Low | $726.09 | $366.54 |
Enterprise Value | $121.14B | $115.83B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,016.33, down 0.7% on the day, with a bearish technical signal despite strong analyst support. The company reported 2025 revenue of $9.22B and net income of $1.35B, with profitability improving but recent quarterly EPS misses. Cash flow trends show aggressive capital expenditure with negative net cash flow in 2025. The stock benefits from AI infrastructure partnerships and a 74.5% analyst buy rating.
Outlook remains positive due to AI-driven demand and global data center expansion, but high valuation multiples and rising debt levels pose risks. The consensus price target of $1,110 suggests upside potential, though technical indicators signal near-term caution. Key catalysts include Q2 2026 earnings and execution on growth investments.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
